FindTrial
Sign In

Golimumab 50 mg

BIOLOGICAL7 trials

Sponsors

Centocor, Inc., Janssen Research & Development, LLC, MedImmune LLC

Conditions

Arthritis, RheumatoidAxial SpondyloarthritisColitis, UlcerativeRheumatoid Arthritis

Phase 2

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
CompletedNCT00487539
Janssen Research & Development, LLCColitis, Ulcerative
Start: 2007-08-31End: 2010-10-31Updated: 2014-02-17
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
CompletedNCT01715896
MedImmune LLCRheumatoid Arthritis
Start: 2013-03-31End: 2015-02-28Updated: 2016-10-31

Phase 3

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
CompletedNCT00264550
Centocor, Inc.Rheumatoid Arthritis
Start: 2005-12-31End: 2012-05-31Updated: 2014-04-29
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
CompletedNCT00299546
Centocor, Inc.Arthritis, Rheumatoid
Start: 2006-02-28End: 2012-05-31Updated: 2014-02-27
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
CompletedNCT00488631
Janssen Research & Development, LLCColitis, Ulcerative
Start: 2007-09-30End: 2015-02-28Updated: 2016-04-26
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
TerminatedNCT02437162
Janssen Research & Development, LLCAxial Spondyloarthritis
Start: 2015-09-03End: 2017-09-06Updated: 2025-04-29
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
TerminatedNCT02438787
Janssen Research & Development, LLCAxial Spondyloarthritis
Start: 2015-07-31End: 2017-08-31Updated: 2025-04-29

Related Papers

Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies
Crohn s & Colitis 3602023-07-014 citations
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials
Advances in Therapy2023-03-3015 citations
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
Therapeutic Advances in Gastroenterology2022-01-018 citations
Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
2020-01-2216 citations
Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data
Journal of Crohn s and Colitis2019-03-0116 citations
A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials
Journal of Crohn s and Colitis2019-01-2418 citations
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Lara D. Veeken2018-09-1927 citations
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
2018-06-26268 citations
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
Journal of Crohn s and Colitis2018-06-1734 citations
Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis.
2017-06-1232 citations
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
2016-11-2436 citations
Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
The Journal of Rheumatology2016-11-0139 citations
Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis
Alimentary Pharmacology & Therapeutics2015-06-2985 citations
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.
2015-01-2237 citations
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
2013-06-14530 citations
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
2013-06-02701 citations
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
2013-05-1534 citations
Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
2012-04-1529 citations
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.
2010-11-1725 citations
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
2009-06-26380 citations